Docetaxel Injection concentrate
| Product Name | Docetaxel Injection concentrate 80 mg/2 ml with solvent (Combipack) |
| Brand Name | ------ |
| Composition | Anhydrous docetaxel 80 mg Solvent (Alcohol 95% v/v) 13%w/v |
| Packing | Vial + Solvent |
| Available strength | 80 mg / 2 mL |
| Therapeutic use | • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC • Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction • Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN |